Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Beta-Alanine" patented technology

Β-Alanine (or beta-alanine) is a naturally occurring beta amino acid, which is an amino acid in which the amino group is at the β-position from the carboxylate group (i.e., two atoms away, see Figure 1). The IUPAC name for β-alanine is 3-aminopropanoic acid. Unlike its counterpart α-alanine, β-alanine has no stereocenter.

Amino acid compositions

A solid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is beta alanine, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the solid supplement composition comprises an amount of nitrate ion (NO3−) that is at least about 1 mg. A semisolid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is beta alanine, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the semisolid supplement composition comprises an amount of nitrate ion (NO3−) that is at least about 1 mg.
Owner:THERMOLIFE INTERNATIONAL LLC

Anti-anxiety composition

An anti-anxiety composition includes 2 grams of Beta Alanine; 0.75 grams of agmatine sulfate; 0.75 grams of taurine; 0.75 grams of magnesium citrate; and 100 mg of l-theanine. A method for decreasing anxiety in a subject includes administering to the subject a drinkable liquid that includes 0.25-2 grams of Beta Alanine.
Owner:RAVNAAS BRENT

Peripheral nerve agonists suppress inflammation

ActiveUS12508241B2AntipyreticAnalgesicsDiseasePseudo allergy
Provided herein are methods of treating conditions associated with activation or over-activation of mast cells is acute or chronic urticaria, mastocytosis or any subtype of mastocytosis, pseudo-allergy, any form of dermatitis, such as contact or atopic dermatitis, wound healing, rosacea, acne, or psoriasis, food allergy, or irritable bowel syndrome. The method comprises administering a MRGPRD agonist, such as beta alanine, GABA, β-AIBA, or 5-oxoETE to a patient to treat the condition. Topical, enteric, delayed-release, or aerosol dosage forms comprising beta-alanine also are provided.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION